Abstract: It is currently hypothesized that increased heart muscle contractility leads to hypertrophic cardiomyopathy (HCM), and reduced contractility leads to dilated cardiomyopathy (DCM). To determine if changes in the core interaction between actin and myosin occur due to mutations in the cardiac actin gene (ACTC), we measured the interactions between myosin and 8 ACTC mutant proteins found in patients with HCM or DCM. R312H showed a decreased actin-activated myosin S1 ATPase rate (13.1 ± 0.63 mol/L/min) compared to WT (15.3 ± 1.6 mol/L/min), whereas the rate with E99K was significantly higher (20.1 ± 1.5 mol/L/min). In vitro motility assays with varying ATP concentrations showed that the K M for E99K remains unchanged with a significantly decreased V max (1.90 ± 0.37 m/sec) compared to WT (3.33 ± 0.46 m/sec). Based on a 5 nm myosin step size, we calculated a duty ratio of approximately 0.04 for WT and the majority of mutant actins; however, the duty ratio for E99K was twice as high. Based on our analysis of 8 ACTC mutants, we infer that mutations in ACTC lead to disease through various molecular mechanisms. While changes in actomyosin interactions with the E99K mutation might cause increased ATP usage and tension leading to HCM, measurable changes in the basic interaction between actin and myosin do not appear to be involved in the mechanisms of disease development for the other ACTC mutants tested.
Introduction
Cardiovascular disease is the leading cause of death in the western world and developing world alike, accounting for health care costs in the billions of dollars each year (Gaziano 2007; Smith 2009 ). In many cases, a pre-existing cardiovascular disease causes heart failure (HF) when the heart muscle cannot pump sufficient blood to organs and tissues. Changes in the proteins and protein interactions in sarcomeres of the heart muscle lead to abnormal heart function, contributing to the disease phenotype and eventual heart failure. Specifically, mutations in genes encoding sarcomeric proteins are involved in the development of either hypertrophic cardiomyopathy (HCM, increased left ventricular wall thickness without chamber expansion) or dilated cardiomyopathy (DCM, thinning of ventricular walls with enlarged chamber volume) (Gaziano 2007; Seidman and Seidman 2011; Smith 2009 ).
Heart muscle contractility relies on repetitive interactions between polymers of ACTC (␣-cardiac actin) protein and the ␤-myosin molecular motor protein generating force through the energy of ATP hydrolysis (Spudich 2001) . In the heart muscle, myosin works in an ensemble to generate force and pump blood. The force of the ensemble (F En ) is described by the expression (Sommese et al. 2013) , F En = f · r · N T , where f is the force generated per actomyosin interaction, N T is the total number of myosin heads able to interact with the actin filament in a half sarcomere, and r is the duty ratio of the actomyosin interaction (the fraction of the total actomyosin ATPase cycle spent doing work). A change in any of the parameters contributing to F En alters the force produced by the muscle and the blood pumped by the heart.This hypothesis was based on the data gathered from studies on myosin motor protein interacting with the thin filament and sarcomeric regulatory proteins (Marston 2011) . For example, a number of ␤-myosin mutants resulted in increased contractility, as reported by increases in the actin-filament velocity using an in vitro motility (IVM) assay, actin activated ATPase activity, and the duty ratio (Moore et al. 2012; Sommese et al. 2013) .
The most extensively studied ACTC mutant is E99K. This mutant protein has been produced in insect cells infected by recombinant baculoviruses (Bookwalter and Trybus 2006; Debold et al. 2010; Mundia et al. 2012; Yates et al. 2007 ) and as a heterozygous mutant in mice (Song et al. 2011) . Based on recent helical reconstruction models of myosin bound to F-actin Lorenz and Holmes 2010) , the E99K-ACTC variant likely disrupts a salt bridge with K569 of myosin. The E99K mutation increased the K M of actin-activated ATPase activity of myosin 4-fold compared to WT, resulting in slower gliding filament velocities (Bookwalter and Trybus 2006) . Reconstituted regulated E99K ACTC filaments (with the troponin/tropomyosin (Tn/Tm) complex) produce lower gliding velocities compared to WT. Recombinant E99K-ACTC-containing thin filaments produced no change in calcium sensitivity (Debold et al. 2010) , while ACTC purified from a transgenic mouse expressing E99K-ACTC resulted in a 2.3-fold increase in EC 50 (concentration required to produce 50% of the effect) compared to WT (Song et al. 2011) .
We have previously demonstrated that some actin mutants exhibit changes in protein stability, whereas other mutants do not and behave much like WT actin (Mundia et al. 2012 ). In the latter cases, altered interactions between actin and binding partners may be involved in heart disease development. Changes in actomyosin activity, like those seen with the E99K-ACTC mutation or mutations in myosin leading to HCM, are among the candidates for the principle cause of this disease.
To test the hypothesis that cardiomyopathies result from altered actomyosin interactions leading to changed contractility, we studied the interaction between myosin and 8 currently known mutants of cardiac actin (Fig. 1) , by examining their biochemical and biophysical properties in vitro. To begin, we examined the impact of mutations on purified proteins, understanding that in the physiological context, patients are likely heterozygous for these mutations. We found that the altered actomyosin interaction observed with E99K-actin resulted in lower gliding velocity and larger (>2×) duty ratio compared to WT-actin. Our results infer multiple pathways to disease development, identifying a primary change associated with the E99K-actomyosin interaction that supports the hypothesis that enhanced contractility leads to HCM, while the remaining ACTC mutations follow different molecular mechanisms. Therefore, it will be important to correlate the specific molecular effects of mutations in sarcomeric proteins with the disease states of individuals to develop targeted treatments.
Methods and materials

Purification of recombinant ACTC proteins
Recombinant ACTC proteins were expressed using a baculovirus/Sf9 system as described previously (Mundia et al. 2012) . Briefly, mutant human ACTC cDNA was produced by site-directed mutagenesis in the pAcUW2Bmod transfer vector and recombinant baculoviruses generated by co-transfection with linearized BakPak6 DNA (Clontech, Mountain View, California, USA) into Sf21 cells using standard methods. Sf21 cells (0.5 × 10 6 total) were infected at a multiplicity of infection of one for 72 h at 27°C. Infected cells were harvested by centrifugation, washed in PBS, and lysed in a high-Tris buffer as outlined in (Mundia et al. 2012 ). The cleared lysate was then filtered through glass wool to remove lipids, and the recombinant actin was purified by DNase-I affinity chromatography (Rutkevich et al. 2006) . Purified actin was stored on ice and used within three days, or stored at −80°C before use.
Purification of myosin
Myosin and subfragment-1 (S1) were prepared from rabbit soleus tissue, as previously described (Margossian and Lowey 1982) . Myosin from soleus tissue is employed in analyses of cardiac-specific sarcomere protein mutations (Lin et al. 1996; Mathur et al. 2011) , because the soleus muscle contains a high proportion of slowtwitch fibres expressing high levels of the same ␤-myosin isoform expressed in the ventricles of hearts (Cuda et al. 1993; Lompré et al. 1984; Mahdavi et al. 1984) . Therefore, data obtained with soleus-derived myosin can be applied to cardiac protein functions involved in heart disease states. Following myosin purification, S1 was prepared by papain digestion to produce EDTA·S1. Full-length myosin was stored in 50% glycerol at −20°C. EDTA·S1 was flashfrozen and stored at −80°C.
Actin-activated myosin ATPase assay
ATPase activity of myosin S1 activated by filamentous actin was examined using the NADH-coupled ATPase assay adapted from Kiianitsa et al. (2003) . ADP produced by myosin ATPase activity was regenerated into ATP through the action of pyruvate kinase converting phosphoenol pyruvate to pyruvate. The subsequent oxidation of NADH when pyruvate is converted to lactate by lactate dehydrogenase was then observed spectrophotometrically. Actin was polymerized overnight at 4°C under polymerizing conditions (25 mmol/L Tris·HCl, pH 7.5, 50 mmol/L KCl, 2 mmol/L MgCl 2 , 1 mmol/L EGTA, 0.1 mmol/L DTT) to a final concentration of 6.25 mol/L actin. The ATP regenerating system (lactate dehydrogenase 4 U/mL, pyruvate kinase 20 U/mL, 500 mol/L phosphoenol pyruvate) (Sigma-Aldrich, St. Louis, Missouri, USA) was then added with NADH (356 mol/L). Upon the addition of myosin S1 in solution together with ATP (0.625 mol/L and 1 mmol/L, respectively), readings were taken at 340 nm every 30 s for 1 h to determine the decline in NADH over time. Slopes of the linear portion of each set of readings were taken and multiplied by the (Colour online) ACTC variants related to heart disease. The HCM-related residues studied in this work are shown in green; DCM-related residues are in red. Residues in grey were not part of this study. Bound nucleotide is shown in the centre of the molecule. This representation was generated using PyMol Viewer (PBD:1ATN). The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.
inverse slope of the NADH standard curve with an r 2 value of 0.99 (determined experimentally) to determine S1 ATPase rates.
In vitro motility assay
The velocities of mutant actin filaments were examined when they interacted with full-length myosin from soleus tissue in the presence of 2 mmol/L ATP (saturating conditions). Monomeric actin was polymerized overnight at 4°C with the addition of 10× polymerization buffer and equimolar rhodamine phalloidin (Cytoskeleton, Denver, Colorado, USA). Myosin was diluted to 0.5 mg/mL using assay buffer (25 mmol/L KCl, 25 mmol/L imidazole·HCl, pH 7.5, 1 mmol/L K 2 H 2 EGTA, 4 mmol/L MgCl 2 , 10 mmol/L DTT) and flowed over nitrocellulose-coated cover slips to bind for 2 min. Assay buffer containing bovine serum albumin (1 mg/mL) was then flowed over the coverslip to block protein binding sites on the surface. Fluorescently labeled actin filaments, diluted with assay buffer (to about 0.1 mol/L), were then flowed over the coverslip and allowed to bind for 2 min. Movement was initiated upon the addition of motility buffer (25 mmol/L KCl, 25 mmol/L imidazole·HCl, pH 7.5, 1 mmol/L K 2 H 2 EGTA, 4 mmol/L MgCl 2 , 10 mmol/L DTT, 2 mmol/L Na 2 H 2 ATP) and an oxygen-scavenging system to retard photobleaching (25 g/mL glucose oxidase, 45 g/mL catalase, and 1% w/v glucose). Filaments were visualized by Zeiss Axiovert 200 inverted scope (Zeiss, Jena, Germany) with a TX2 (510 nm) fluorescence filter. Video records were captured using an Andor Luca camera (Andor Technology, Belfast, Ireland) with Zeiss plan NEOFLUOR 100/1.30 oil objective and Andor Luca software at a frame rate of 0.12711 frames/s. Individual actin filaments moving in a linear pattern were selected for measurement. Velocities for these filaments were determined by measuring total distance traveled over frame length using a calibration of 5.6 pixels/m. Twenty-five to thirty filaments were measured for each actin mutant per condition from at least 2 batches of purified protein.
Filaments were selected based on linear movement over a minimum of 6 frames.
Statistical analysis
Standard deviations for all results were calculated using Microsoft Excel (Microsoft Office, 2008, Redmond Washington, USA). Statistical differences were determined by an unpaired Student's t-test using Graphpad quick calcs (Graphpad software, San Diego, California, USA).
Results and discussion
Actin activated myosin ATPase
To test the hypothesis that mutations in ACTC cause changes in actomyosin activity, similar to mutations in the ␤-myosin gene, 8 actin mutants were expressed and purified using a baculovirus expression system ( Fig. 2A) , and their effect on the actin-activated myosin ATP hydrolysis rate (ATPase) was determined ( Table 1) .
The R312H actin mutant consistently showed decreased ATPase activity (13.1 ± 0.63 mol/L/min) compared to WT actin (15.3 ± 1.58 mol/L/min), likely as a result of overall instability of this mutant (Mundia et al. 2012; Vang et al. 2005; Wong et al. 2001) . Interestingly, myosin ATPase activity in the presence of E99K actin was significantly higher at 20.1 ± 1.46 mol/L/min compared to all other mutants and WT. This result with E99K suggests a deregulation of the actomyosin interaction and a higher utilization of ATP. The other 6 ACTC mutants resulted in no change in myosin ATPase activity.
In vitro motility
The velocity of unregulated actin filaments propelled by myosin from soleus tissue was determined with an in vitro motility assay in the presence of 2 mmol/L ATP and 25 mmol/L KCl (Fig. 2B) . A230V-and E99K-actin mutants exhibited significantly reduced velocity compared to WT actin (p < 0.005). The filament velocity is dependent on the duty ratio and step size of the motor and the efficiency of ATP hydrolysis and product release (Huxley 1990; Siemankowski et al. 1985) . To determine the effect of actin mutants on the V max and K M of actomyosin gliding velocity, in vitro motility assays were performed with WT, E99K, and M305L actin mutants with 25 mmol/L KCl and 0-2 mmol/L ATP. The E99K mutant was investigated because of the reduction in its velocity compared to WT actin (Fig. 2B ) and the location of the substitution in the actomyosin interface . M305L actin was selected to compare an ACTC mutant that exhibited comparable velocity and intrinsic properties to WT (Mundia et al. 2012) . WT ACTC was used as an internal control. The filament velocity data were fitted to a hyperbolic function (Michaelis-Menten kinetics), and the maximum velocity (V max ) and the Michaelis-Menten constant (K M ) were calculated (Fig. 2C) . E99K actin demonstrated a significantly decreased V max (1.90 ± 0.37 m/s) compared to WT (3.33 ± 0.46 m/s) and M305L (3.38 ± 0.44 m/sec). The K M values for WT, E99K, and M305L actin (0.070 ± 0.042 mol/L, 0.084 ± 0.059 mol/L, and 0.087 ± 0.046 mol/L, respectively) were not statistically different from each other.
We next calculated the duty ratio (r) for each variant actomyosin complex using the velocity (v o ) determined from in vitro motility assays and ATPase (k cat ) measurement using the expression, r = ␦ · k cat /v o, where ␦ is the step size of the myosin motor (Table 1) . We took ␦ to be about 5 nm (Mehta et al. 1997; Molloy et al. 1995) . The calculated duty ratio for WT actin was about 0.04. Most of the actin mutants produced a duty ratio similar to that of WT actin, with the notable exception of E99K actin. In E99K, the cumulative effect of high ATPase activity (k cat ) and low velocity (v o ) resulted in a duty ratio over 2-fold larger than that of WT actin. Our observations with E99K are confirmed by the first characterization of E99K ACTC protein resulting in lower in vitro motility assay velocities and increased ATPase activities using cardiac myosin (Bookwalter and Trybus 2006 ). An increase in duty ratio supports the idea that the E99K mutation causes an increase in ATP usage and tension, contributing to HCM.
Comparison between ACTC mutations
Our work expands investigations of cardiac actin mutations found in the literature, extending the question of altered actomyosin interactions to ACTC mutations beyond E99K. Müller et al. (2012) purified Y166C and M305L proteins and found that both reduced cardiac myosin ATPase activity to about half that of WT. In contrast, our work showed ATPase activities with these mutants similar to WT, with calculated duty ratios that are only slightly elevated compared to WT. Differences in expression and purification systems and the use of full-length myosin versus myosin S1 might account for these distinctions.
Since we found that all other actin mutants examined manifested actomyosin duty ratios similar to those of WT actin, what would be the cause of HCM with these actin mutants? It is first important to recognize the limitations of the data presented here. Our biochemical analyses examined only unloaded interactions between actin and myosin at 25 mmol/L KCl. Effects with actin mutants at the actomyosin interface may require more physiological conditions to be apparent. For example, the E99K mutation has been studied in the context of regulated thin filaments (Debold et al. 2010) , in a transgenic mouse (Song et al. 2010) , and more recently, in reconstituted myocardia (Bai et al. 2014a ). These more biologically complex systems suggest that the heart compensates to overcome the increased duty ratio observed in unregulated E99K filaments. Specifically, the presence of Tm/Tn in reconstituted myocardia led to recovery of the diminished tension observed in myocardia reconstituted with E99K actin protein alone (Bai et al. 2014a ). Alternatively, lower tension was observed in A331P reconstituted myocardia in the presence of Tm/Tn (Bai et al. 2014b) . Interestingly, our data show a slightly lower duty ratio with A331P, which might contribute to the lower tension observed in reconstituted myocardia.
Alternatively, all ACTC mutations might not interfere directly with the actomyosin interface. Some actin mutations (M305L, A331P, A295S) might affect interactions with tropomyosin ), whereas other mutations (A331P, E361G) alter myosin binding protein-C binding (Chow et al. 2014) or actin polymerization (Y166C) (Mundia et al. 2012) . In addition to E99K, other HCMlinked ACTC mutations are found in actin subdomain 1 (H88Y, F90⌬, and R95C, Fig. 1 ) near the actomyosin interface. Given their location, these mutations might affect the actomyosin core interactions in a manner similar to the E99K mutation.
An additional consideration is that all actin mutations related to cardiomyopathies have been discovered through candidate gene approaches. It has been assumed that the disease phenotype of patients is a direct outcome of the ACTC gene mutation, when in reality the disease may be due to a mutation(s) in a different gene(s), or to nongenetically acquired changes. The penetrance of a mutation increases the confidence that a particular mutation is causative; however, with ACTC, the number of identified mutations is small and the frequency is likewise low. For example, no ACTC changes were found in Japanese and South African DCM patients (Mayosi et al. 1999; Takai et al. 1999) . The HCM-related A331P mutation has been observed in one patient looking only at the ACTC gene (Olson et al. 2000) . In the same study, the E99K actin mutation was found as an autosomal dominant mutation in two families over three generations (Olson et al. 2000) , while a separate study found the E99K mutation in 5 patients out of 247 with cardiomyopathies (Monserrat et al. 2007) , increasing the chances that this mutation is linked to HCM. Taken together, we must be careful when considering the connections between a specific sarcomere protein and the development of a disease phenotype, as there are networks of molecular interactions making up the working sarcomere.
Conclusion
Our results suggest that there are multiple pathways to the development of cardiomyopathies through mutations in the cardiac actin gene. The E99K actin mutant fits the general hypothesis that a mutation leading to an increase in contractility causes HCM. Such an increase in contractility would affect overall ATP usage in the heart, leading to the HCM disease phenotype. However, the application of this hypothesis to other actin mutants may not be straightforward. Our experiments highlight the need to integrate molecular changes with alterations in tissues and suggest the potential for compensatory changes to account for molecular deficiencies in the actomyosin interaction.
